RxDoctor Payments Data

Kayla Holzer

Family · Bismarck, NDNPI 1649901869

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.9% of the total across 326 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in ND with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,423in general payments, 2019–2025

Across 326 payments — averaging $16.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$970
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$821
  • Pfizer$503
  • Amgen$467
  • Lilly USA, LLC$455
  • AstraZeneca$326
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$5,36299%
  • Education$611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,423 in reported general payments places this provider in the 95th percentile of 496 family providers in North Dakota.

See all family providers in North Dakota

Medicare billing

Part B allowed, 2024
$31,642
Medicare patients
141
Services billed
539

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide38$40,473
EliquisApixaban37$18,509
JardianceEmpagliflozin19$7,261
Spiriva RespimatTiotropium Bromide11$5,795
Tramadol Hcl ErTramadol Hcl12$2,760
SynthroidLevothyroxine Sodium11$1,351
Liothyronine Sodium29$1,199
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,179
Levothyroxine Sodium80$1,074
Hydralazine Hcl52$515
Methenamine Hippurate24$413
Famotidine31$412
Pregabalin19$405
Furosemide84$400
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide17$399

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$455$40,47338 claims
PfizerEliquis$503$18,50937 claims
Boehringer IngelheimJardiance, Spiriva Respimat$13$13,05630 claims
AbbVieSynthroid$970$1,35111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 496 family providers in North Dakota.

Other family in Bismarck

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →